DexCom, Inc. (DXCM) reported second-quarter 2026 adjusted earnings per share (EPS) of 70 cents, exceeding the Zacks Consensus Estimate of 61 cents by 14.8%. This marks an increase from the adjusted EPS of 48 cents in the same quarter last year. Revenues rose 13.1% year over year to $1.31 billion, surpassing estimates slightly by 1.01%.
In the U.S., revenues were $933.4 million, up 11% year over year, bolstered by new patient additions and increased share capture. International revenues experienced a more significant growth of 19% to $375 million, aided by reimbursement expansion in markets like France and Canada. DexCom’s adjusted gross profit reached $838.5 million, up 20.6% from the prior year, indicating an adjusted gross margin of 64.1%.
Following these results, DexCom raised its 2026 revenue guidance to $5.18-$5.25 billion, reflecting expected annual growth of 11-13%. The updated forecast for adjusted gross margin stands at approximately 64%, with adjusted operating margin guidance increased to 23.5-24% from previous estimates.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
